Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 3/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | RARB | P10826 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3015275 | 0.93 | BLM (0.41) | BLMPTPN1CA1CA12CA2 | |
| SCHEMBL8371885 | 0.91 | BLM (0.39) | BLMRARBALDH1A1LMNA | |
| SCHEMBL28668624 | 0.91 | BLM (0.39) | BLMRARBALDH1A1LMNA | |
| SCHEMBL3008997 | 0.91 | BLM (0.39) | BLMRARBALDH1A1LMNA | |
| SCHEMBL27719291 | 0.91 | BLM (0.39) | BLMRARBALDH1A1LMNA | |
| SCHEMBL15264 | 0.91 | BLM (0.39) | BLMRARBALDH1A1LMNA | |
| SCHEMBL29164384 | 0.90 | BLM (0.38) | BLMPTPN1RARBALDH1A1LMNA | |
| SCHEMBL27579861 | 0.90 | BLM (0.38) | BLMPTPN1RARBALDH1A1LMNA | |
| SCHEMBL15512289 | 0.86 | ALDH1A1 (0.37) | ALDH1A1 | |
| SCHEMBL28034 | 0.86 | CA1 (0.46) | BLMCA1CA12CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022228652-A1 | MEANS AND METHOD FOR TREATING VIRAL INFECTIONS | BIRKENMEIER GERD (DE) | 2022-11-03 | — | — | WO | disclosed |
| EP-1874407-B1 | SUBSTANCES AND PHARMACEUTICAL COMPOSITIONS FOR THE INHIBITION OF GLYOXALASES AND THEIR USE AS ANTI-FUNGAL AGENTS | BIOMAC PRIVATINSTITUT FÜR MEDIZINISCHE UND ZAHNMEDIZINISCHE FORSCHUNG ENTWICKLUNG UND DIAGNOSTIK GMB (DE) | 2015-09-09 | — | — | EP | disclosed |
| US-8859001-B2 | Fenoldopam formulations and pro-drug derivatives | LEVITE MIA (IL) | 2014-10-14 | — | — | US | disclosed |
| EP-1877141-B1 | SUBSTANCES AND PHARMACEUTICAL COMPOSITIONS FOR THE INHIBITION OF GLYOXALASES AND THEIR USE AGAINST BACTERIA | BIOMAC PRIVATINSTITUT FUER MEDIZINISCHE UND ZAHNMEDIZINISCHE FORSCHUNG ENTWICKLUNG UND DIAGNOSTIK GM (DE) | 2013-06-12 | — | — | EP | disclosed |
| US-20110104287-A1 | FENOLDOPAM FORMULATIONS AND PRO-DRUG DERIVATIVES | LEVITE MIA | 2011-05-05 | — | — | US | disclosed |
| US-7919113-B2 | Microemulsion; increased stability; delivery system with high bioavailability of water insoluble substances | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2011-04-05 | — | — | US | disclosed |
| US-20100204161-A1 | Substances and Pharmaceutical Compositions for the Inhibition of Glyoxalases and Their Use Against Bacteria | BIOMAC PRIVATINSTITUT FUR MEDIZINISHE UND ZAHMEDIZ FORSCHUNG, ENTWICKLUNG UND DIAGNOSTIK GMBH (DE) | 2010-08-12 | — | — | US | disclosed |
| WO-2009052491-A2 | FENOLDOPAM FORMULATIONS AND PRODRUG DERIVATIVES | GERAGHTY, ERIN (US) | 2009-04-23 | — | — | WO | disclosed |
| EP-1095935-B1 | 6-Hydroxy-5,6-dihydrouracils as herbicides | SUMITOMO CHEMICAL CO (JP) | 2008-12-17 | — | — | EP | disclosed |
| US-20080300303-A1 | Substances and Pharmaceutical Compositions for the Inhibition of Glyoxalases and Their Use As Anti-Fungal Agents | BIOMAC PRIVATINSTITUT FUER MEDIZINISCHE UND ZAHNMEDIZINISCHE FORSCHUNG, ENTWICKLUNG UND DIAGNOSTIK GMBH (DE) | 2008-12-04 | — | — | US | disclosed |
| EP-1874407-A2 | SUBSTANCES AND PHARMACEUTICAL COMPOSITIONS FOR THE INHIBITION OF GLYOXALASES AND THEIR USE AS ANTI-FUNGAL AGENTS | Biomac Privatinstitut für medizinische und Zahnmedizinische Forschung, Entwicklung und Diagnostik GmbH (DE) | 2008-01-09 | — | — | EP | disclosed |
| WO-2006108679-A2 | SUBSTANCES AND PHARMACEUTICAL COMPOSITIONS FOR THE INHIBITION OF GLYOXALASES AND THEIR USE TO COMBAT CANCER | BIOMAC PRIVATINSTITUT FÜR MEDIZINISCHE UND ZAHNMEDIZINISCHE FORSCHUNG, ENTWICKLUNG UND DIAGNOSTIK GMBH (DE) | 2006-10-19 | — | — | WO | disclosed |
| WO-2006108682-A2 | SUBSTANCES AND PHARMACEUTICAL COMPOSITIONS FOR THE INHIBITION OF GLYOXALASES AND THEIR USE AS ANTI-FUNGAL AGENTS | BIOMAC PRIVATINSTITUT FÜR MEDIZINISCHE UND ZAHNMEDIZINISCHE FORSCHUNG, ENTWICKLUNG UND DIAGNOSTIK GMBH (DE) | 2006-10-19 | — | — | WO | disclosed |
| WO-2006108680-A2 | SUBSTANCES AND PHARMACEUTICAL COMPOSITIONS FOR THE INHIBITION OF GLYOXALASES AND THEIR USE AGAINST PROTOZOA AND HELMINTHES | BIOMAC PRIVATINSTITUT FÜR MEDIZINISCHE UND ZAHNMEDIZINISCHE FORSCHUNG, ENTWICKLUNG UND DIAGNOSTIK GMBH (DE) | 2006-10-19 | — | — | WO | disclosed |
| EP-1101761-B1 | Process for producing 3-phenyluracil compounds | SUMITOMO CHEMICAL CO (JP) | 2005-08-17 | — | — | EP | disclosed |
| US-20050158389-A1 | Dispersible concentrate lipospheres for delivery of active agents | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM | 2005-07-21 | — | — | US | disclosed |
| US-6410484-B1 | ACTIVE MATERIAL; CONTROLLING WEEDS | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-06-25 | — | — | US | disclosed |
| US-6339155-B1 | Process for producing 3-phenyluracil compounds | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-01-15 | — | — | US | disclosed |
| EP-1101761-A2 | Process for producing 3-phenyluracil compounds | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2001-05-23 | — | — | EP | disclosed |
| EP-1095935-A1 | 6-Hydroxy-5,6-dihydrouracils as herbicides | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2001-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110104287-A1 | FENOLDOPAM FORMULATIONS AND PRO-DRUG DERIVATIVES | NAPEPLD, PNLIP, NPSR1 | BLM 4354/4885PTPN1 2460/4885CA1 4869/4885 |
| US-20080300303-A1 | Substances and Pharmaceutical Compositions for the Inhibition of Glyoxalases and Their Use As Anti-Fungal Agents | GLO1, G6PD, GRHPR | BLM 3322/4885PTPN1 2171/4885CA1 545/4885 |
| US-20100204161-A1 | Substances and Pharmaceutical Compositions for the Inhibition of Glyoxalases and Their Use Against Bacteria | GLO1, G6PD, GRHPR | BLM 2027/4885PTPN1 1451/4885CA1 674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.